Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
Status:
Terminated
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this project is to describe the pathophysiology of thrombocytopenia and
bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to
thrombopoietic agents in vitro and in vivo.